Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Has The Anakinra Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, there has been a significant surge in the market size of Anakinra. Projected growth from 2024 estimates the market to be worth $4.89 billion and expanding to $5.51 billion in 2025 with a Compound Annual Growth Rate (CAGR) of 12.8%. The historical growth trajectory can be linked to the surge in cases of rheumatoid arthritis, the endorsement of Anakinra in treating uncommon autoinflammatory diseases like NOMID, heightened awareness of biologics in the management of recurring inflammatory conditions, and the increasing preference for targeted therapies.

In the ensuing years, the market size for anakinra is projected to experience accelerated growth, with an estimated value of $8.81 billion by 2029, boasting a 12.4% compound annual growth rate (CAGR). Key factors contributing to this projected growth span the board, including the expanding indications for anakinra in various conditions, a heightened interest in personalized medicine, the increasing prevalence of uncommon autoinflammatory disorders, progress in drug delivery systems, and enhanced healthcare accessibility in emerging markets promoting the demand for biologics. Future trends forecasted include the production of biosimilars and next-generation IL-1 inhibitors, a shift towards home-based and self-administered treatments, strategic partnerships between biotech firms and academic institutions, and an increased utilization of digital health solutions to bolster patient adherence.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

What are the Fundamental Drivers and Innovations Shaping the Anakinra Market?

The surge in cases of autoimmune disorders, where the body’s immune system mistakenly targets and destroys healthy tissues and organs, is slated to fuel the anakinra market’s expansion. Autoimmune disorders are typically caused by a combination of genetic predisposition and environmental influences, such as infections, pollution, and alterations in diet. Anakinra works to curb these disorders through interruption of interleukin-1 (IL-1) activity, thereby lessening inflammation in ailments like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. As an example, the Australian Institute of Health and Welfare reported in June 2024 that in 2021-22, rheumatoid arthritis hospitalizations increased 25% from the prior year, totaling 10,000, or 39 hospitalizations per 100,000 population. Therefore, the escalating frequency of autoimmune disorders is propelling the anakinra market. Additionally, the increase in healthcare expenditure is anticipated to drive the anakinra market’s upward trend. Healthcare expenditure encompasses the total funds spent on healthcare services and products, from hospital care and physician services to medications, devices, public health initiatives and more. The rise in healthcare expenditure is influenced by factors such as a growing elderly population, advancements in medicine, prevalence of chronic diseases, higher drug costs, increased healthcare use, administrative expenses, and inflation. Funds spent on healthcare bolster the anakinra market by promoting anakinra’s development, availability, and constant administration as an effective remedy for inflammatory conditions like rheumatoid arthritis, and by aiding its integration into healthcare systems via insurance coverage and patient access schemes. In May 2023, the Office for National Statistics reported that in 2022, the UK’s healthcare expenditure swelled to nearly $352 billion (£283 billion), a 0.7% nominal increase from 2021. Consequently, the upswing in healthcare expenditure is contributing to the anakinra market’s growth.

How Is the Anakinra Market Segmented?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

Which Regions Are Driving the Next Phase of the Anakinra Market Growth?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Anakinra Market?

Principal businesses in the Anakinra market are securing regulatory assents to include indications for innovative therapeutic uses. Such authorizations are essentially official permissions from government bodies which, after assessing the safety, effectiveness, and quality of a drug, allow it to be marketed and suggested for certain illnesses. In November 2022, for example, the US government body, the Food and Drug Administration, issued an Emergency Use Authorization (EUA) for Kineret (anakinra) to administer treatment to adult patients hospitalized with pneumonia due to COVID-19 who required additional oxygen, with the goal of minimizing the probability of serious respiratory failure. The affirmation was on the basis of the SAVE-MORE Phase 3 study, demonstrating that preemptive treatment with Kineret enhanced patient outcomes. Kineret operates by obstructing cytokines IL-1a and IL-1ß which catalyze the extreme inflammatory response seen in critical cases of COVID-19. Even though it doesn’t have full FDA approval for this specific indication, it has been authorized for transitory use in the course of the public health crisis.

View the full report here:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

How Is the Anakinra Market Defined and What Are Its Core Parameters?

Anakinra refers to a biopharmaceutical medication that acts as a recombinant version of the human interleukin-1 receptor antagonist. It is generally used to treat moderate-to-severe rheumatoid arthritis in individuals who have not reacted well to other disease-modifying antirheumatic medications.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21095

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model